checkAd
    Startseite > Aktien > Cidara Therapeutics > Nachrichten
    Cidara Therapeutics Aktie
    12,350
     
    USD
    0,00 %
    0,000 USD
    Letzter Kurs 02:00:00 NYSE
    11,900
     
    USD
    100 STK
    Geldkurs 24.04.24
    12,830
     
    USD
    100 STK
    Briefkurs 24.04.24
    ISIN: US1717572069 · WKN: A3D4A6 · SYM: CDTX · USA

    Neueste Nachrichten

    Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
    24.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
    24.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Reverse Stock Split
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
    05.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
    06.03.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
    12.02.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
    29.01.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces European Approval of REZZAYO (rezafungin) for the Treatment of Invasive Candidiasis in Adults
    22.12.23 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
    30.11.23 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
    20.11.23 · globenewswire · Cidara Therapeutics